AR065316A1 - Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales - Google Patents
Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias unguealesInfo
- Publication number
- AR065316A1 AR065316A1 ARP080100602A ARP080100602A AR065316A1 AR 065316 A1 AR065316 A1 AR 065316A1 AR P080100602 A ARP080100602 A AR P080100602A AR P080100602 A ARP080100602 A AR P080100602A AR 065316 A1 AR065316 A1 AR 065316A1
- Authority
- AR
- Argentina
- Prior art keywords
- chitosan
- acceptable salt
- chitosans
- physiologically acceptable
- nail
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Uso de quitosanos, derivados de quitosano y sales fisiologicamente aceptables de éstos para el tratamiento de enfermedades inflamatorias ungueales. La presente también se dirige al uso de quitosanos, un derivado de quitosano o una sal fisiologicamente aceptable del mismo, para acelerar el ritmo de crecimiento de la una. La presente además está dirigida al uso de quitosanos para acelerar el ritmo de crecimiento de las unas durante el tratamiento de enfermedades ungueales, distrofia ungueal u otras afecciones ungueales, para acortar de forma considerable los tratamientos específicos de dichas enfermedades ungueales, distrofia ungueal u otras afecciones ungueales. Reivindicacion 1: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, caracterizado porque es usado para la aceleracion del ritmo de crecimiento de la una. Reivindicacion 8: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque se administra en combinacion con uno o más principios activos. Reivindicacion 9: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque dicho principio activo es para el tratamiento de una enfermedad de la una. Reivindicacion 11: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con la reivindicacion 9, caracterizado porque dicho principio activo se selecciona de corticosteroides, agentes antipsoriásicos, agentes inmunosupresores, agentes antimicoticos, agentes antisépticos, humectantes, y/o agentes fortalecedores de unas. Reivindicacion 12: Quitosano, derivado de quitosano soluble en agua y/o una sal fisiologicamente aceptable de éste, de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizado porque se administra en forma topica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07102335A EP1958638A1 (en) | 2007-02-14 | 2007-02-14 | Use of chitosans to increase nail growth rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065316A1 true AR065316A1 (es) | 2009-05-27 |
Family
ID=38345983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100602A AR065316A1 (es) | 2007-02-14 | 2008-02-12 | Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US8680074B2 (es) |
| EP (3) | EP1958638A1 (es) |
| JP (3) | JP5426401B2 (es) |
| KR (2) | KR101323762B1 (es) |
| CN (2) | CN102988405A (es) |
| AR (1) | AR065316A1 (es) |
| AT (1) | ATE522221T1 (es) |
| AU (1) | AU2008214693B2 (es) |
| BR (1) | BRPI0807595A2 (es) |
| CA (1) | CA2677715C (es) |
| CL (2) | CL2008000444A1 (es) |
| CO (1) | CO6230979A2 (es) |
| CY (2) | CY1112058T1 (es) |
| DK (2) | DK2377541T3 (es) |
| EA (2) | EA201270116A1 (es) |
| ES (2) | ES2436647T3 (es) |
| HR (2) | HRP20110667T1 (es) |
| IL (1) | IL200269A (es) |
| MA (1) | MA31236B1 (es) |
| ME (1) | ME00830B (es) |
| MX (1) | MX2009008686A (es) |
| MY (2) | MY154499A (es) |
| NZ (1) | NZ578896A (es) |
| PH (1) | PH12014500274A1 (es) |
| PL (2) | PL2117564T3 (es) |
| PT (2) | PT2117564E (es) |
| RS (2) | RS52031B (es) |
| SI (2) | SI2377541T1 (es) |
| UA (1) | UA100011C2 (es) |
| WO (1) | WO2008098869A2 (es) |
| ZA (1) | ZA200905443B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10201490B2 (en) | 2007-02-14 | 2019-02-12 | Polichem Sa | Use of chitosans for the treatment of nail inflammatory diseases |
| WO2010109423A1 (en) * | 2009-03-25 | 2010-09-30 | Sulur Subramaniam Vanangamudi | A medicinal antifungal and steroids cream comprising chitosan and a process to make it |
| KR20140096048A (ko) * | 2011-10-05 | 2014-08-04 | 알러간, 인코포레이티드 | 네일 건강을 강화시키는 조성물들 |
| HK1200364A1 (en) * | 2011-12-20 | 2015-08-07 | Laboratoires Urgo | Topical film-forming composition, and use thereof for treating or preventing onychophagia |
| US8697753B1 (en) | 2013-02-07 | 2014-04-15 | Polichem Sa | Method of treating onychomycosis |
| EP2845597A1 (en) * | 2013-09-10 | 2015-03-11 | Polichem S.A. | Hydroxypropyl chitosan for the treatment of onychomycosis |
| EP2910245A1 (en) * | 2014-02-21 | 2015-08-26 | Polichem SA | Topical antifungal composition for treating onychomycosis |
| CN109893472A (zh) * | 2019-04-09 | 2019-06-18 | 涿州皓原箔业有限公司 | 一种环保无毒水性卸甲液及其制备方法 |
| ES2834732B2 (es) * | 2019-12-17 | 2022-03-24 | Univ Valladolid | Solucion acuosa que comprende un complejo de inclusion, metodo de obtencion y su uso para aplicacion en cultivos y la mejora de su rendimiento |
| CN111388416B (zh) * | 2020-02-26 | 2022-03-08 | 浙江康德药业集团股份有限公司 | 一种盐酸利多卡因胶浆剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3541305A1 (de) * | 1985-11-22 | 1987-05-27 | Wella Ag | Kosmetische mittel auf der basis von n-hydroxypropylchitosanen, neue n-hydroxypropyl-chitosane sowie verfahren zu ihrer herstellung |
| DE3723811A1 (de) * | 1987-07-18 | 1989-01-26 | Wella Ag | Nagellack auf der basis von o-benzyl-n-hydroxyalkylchitosanen sowie neue o-benzyl-n-hydroxyalkylderivate des chitosans |
| CA2008775C (en) | 1989-02-24 | 1998-12-22 | Alberto Ferro | Nail lacquer |
| ES2101263T3 (es) | 1993-02-19 | 1997-07-01 | Howard Green | Composiciones que contienen proteinas de corneocitos. |
| FR2718637A1 (fr) * | 1994-04-15 | 1995-10-20 | Oreal | Composition cosmétique à appliquer sur l'ongle. |
| RU2108114C1 (ru) * | 1996-12-27 | 1998-04-10 | Товарищество с ограниченной ответственностью Научно-производственное предприятие "Эрлон", Лтд. | Биологическая композиция для лечения ран "коллахит" |
| ITTO980264A1 (it) | 1998-03-26 | 1999-09-26 | Silvio Rossi | Applicazione di un estratto basico non quaternario della peschiera fuchsiaefolia ad attivita' antimalarica |
| US6391334B1 (en) * | 1999-10-25 | 2002-05-21 | Amway Corporation | Barrier-forming composition |
| DE10035991A1 (de) | 2000-07-24 | 2002-02-14 | Polichem Sa | Nagellackzusammensetzung |
| AU2002351583A1 (en) * | 2001-12-14 | 2003-06-30 | Ism Biopolymer Inc. | Chitosan oligosaccharides and uses thereof |
| EP1440683A1 (de) * | 2003-01-23 | 2004-07-28 | Cognis France S.A. | Verwendung von Oligoglucosaminen in kosmetischen oder dermatologischen Zubereitungen |
| EP1491202A1 (en) * | 2003-06-23 | 2004-12-29 | Polichem S.A. | Nail restructuring compositions for topical application |
| JP3881992B2 (ja) | 2004-07-30 | 2007-02-14 | シャープ株式会社 | 受信装置、受信プログラム、および受信プログラムを記録した記録媒体 |
| WO2006111426A1 (en) * | 2005-04-19 | 2006-10-26 | Galderma S.A. | Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology |
| FR2892023B1 (fr) * | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
| DE102006049585A1 (de) | 2006-10-22 | 2008-04-24 | Susilo, Rudy, Dr. | Nagellack für kosmetische und medizinische Anwendungen |
-
2007
- 2007-02-14 EP EP07102335A patent/EP1958638A1/en not_active Withdrawn
-
2008
- 2008-02-07 ES ES11172347.4T patent/ES2436647T3/es active Active
- 2008-02-07 KR KR1020117012108A patent/KR101323762B1/ko not_active Expired - Fee Related
- 2008-02-07 RS RS20110443A patent/RS52031B/sr unknown
- 2008-02-07 KR KR1020097018790A patent/KR101131015B1/ko not_active Expired - Fee Related
- 2008-02-07 ME MEP-2009-271A patent/ME00830B/me unknown
- 2008-02-07 ES ES08716765T patent/ES2369116T3/es active Active
- 2008-02-07 EP EP11172347.4A patent/EP2377541B1/en active Active
- 2008-02-07 PT PT08716765T patent/PT2117564E/pt unknown
- 2008-02-07 CN CN2012102916935A patent/CN102988405A/zh active Pending
- 2008-02-07 WO PCT/EP2008/051477 patent/WO2008098869A2/en not_active Ceased
- 2008-02-07 JP JP2009549395A patent/JP5426401B2/ja not_active Expired - Fee Related
- 2008-02-07 US US12/449,573 patent/US8680074B2/en not_active Expired - Fee Related
- 2008-02-07 UA UAA200908419A patent/UA100011C2/ru unknown
- 2008-02-07 EP EP08716765A patent/EP2117564B1/en active Active
- 2008-02-07 PL PL08716765T patent/PL2117564T3/pl unknown
- 2008-02-07 ZA ZA200905443A patent/ZA200905443B/xx unknown
- 2008-02-07 DK DK11172347.4T patent/DK2377541T3/da active
- 2008-02-07 HR HR20110667T patent/HRP20110667T1/hr unknown
- 2008-02-07 CN CN2008800049909A patent/CN101663039B/zh not_active Expired - Fee Related
- 2008-02-07 MX MX2009008686A patent/MX2009008686A/es active IP Right Grant
- 2008-02-07 DK DK08716765.6T patent/DK2117564T3/da active
- 2008-02-07 BR BRPI0807595-6A2A patent/BRPI0807595A2/pt not_active IP Right Cessation
- 2008-02-07 SI SI200831116T patent/SI2377541T1/sl unknown
- 2008-02-07 PT PT111723474T patent/PT2377541E/pt unknown
- 2008-02-07 EA EA201270116A patent/EA201270116A1/ru unknown
- 2008-02-07 NZ NZ578896A patent/NZ578896A/en not_active IP Right Cessation
- 2008-02-07 AU AU2008214693A patent/AU2008214693B2/en not_active Ceased
- 2008-02-07 EA EA200901093A patent/EA018390B1/ru not_active IP Right Cessation
- 2008-02-07 MY MYPI20093349A patent/MY154499A/en unknown
- 2008-02-07 CA CA2677715A patent/CA2677715C/en not_active Expired - Fee Related
- 2008-02-07 RS RS20130569A patent/RS53143B/sr unknown
- 2008-02-07 SI SI200830430T patent/SI2117564T1/sl unknown
- 2008-02-07 MY MYPI2014000324A patent/MY163297A/en unknown
- 2008-02-07 PL PL11172347T patent/PL2377541T3/pl unknown
- 2008-02-07 AT AT08716765T patent/ATE522221T1/de active
- 2008-02-12 AR ARP080100602A patent/AR065316A1/es unknown
- 2008-02-12 CL CL200800444A patent/CL2008000444A1/es unknown
-
2009
- 2009-08-06 IL IL200269A patent/IL200269A/en not_active IP Right Cessation
- 2009-09-04 MA MA32200A patent/MA31236B1/fr unknown
- 2009-09-14 CO CO09098720A patent/CO6230979A2/es active IP Right Grant
-
2011
- 2011-11-22 CY CY20111101125T patent/CY1112058T1/el unknown
-
2013
- 2013-07-12 JP JP2013146717A patent/JP2013213048A/ja active Pending
- 2013-07-15 CL CL2013002052A patent/CL2013002052A1/es unknown
- 2013-12-04 CY CY20131101097T patent/CY1115136T1/el unknown
- 2013-12-10 HR HRP20131175AT patent/HRP20131175T1/hr unknown
-
2014
- 2014-01-29 US US14/167,273 patent/US9173827B2/en not_active Expired - Fee Related
- 2014-01-30 PH PH12014500274A patent/PH12014500274A1/en unknown
-
2015
- 2015-08-14 JP JP2015160157A patent/JP6045663B2/ja not_active Expired - Fee Related
- 2015-09-30 US US14/870,684 patent/US20160015620A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065316A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| JP2014505733A5 (es) | ||
| CO6150136A2 (es) | Combinacion de adapaleno y peroxido de benzoilo para tratar lesiones de acne | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| WO2009043437A3 (en) | Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections | |
| WO2009046859A3 (en) | Use of af12198 and dago as therapeutic agents | |
| CL2012000446A1 (es) | Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios. | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| WO2009039982A3 (en) | Use of gip alone or in combination with dynorphin b as a therapeutic agent | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| AR080491A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| WO2009033657A3 (en) | Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents | |
| HK1202448A1 (en) | Topical formulation for administering a compound | |
| BR112012021638A2 (pt) | composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara. | |
| AR065317A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| WO2012125941A1 (en) | Lithium treatment for microbial infections | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| JP2016538288A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |